ATE147629T1 - Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch- immunologischer fehlfunktion - Google Patents

Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch- immunologischer fehlfunktion

Info

Publication number
ATE147629T1
ATE147629T1 AT90914995T AT90914995T ATE147629T1 AT E147629 T1 ATE147629 T1 AT E147629T1 AT 90914995 T AT90914995 T AT 90914995T AT 90914995 T AT90914995 T AT 90914995T AT E147629 T1 ATE147629 T1 AT E147629T1
Authority
AT
Austria
Prior art keywords
neuro
disorders associated
cognitive disorders
systemic
malfunction
Prior art date
Application number
AT90914995T
Other languages
English (en)
Inventor
William A Carter
Original Assignee
Hem Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Pharma Corp filed Critical Hem Pharma Corp
Application granted granted Critical
Publication of ATE147629T1 publication Critical patent/ATE147629T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT90914995T 1989-10-16 1990-10-09 Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch- immunologischer fehlfunktion ATE147629T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42159689A 1989-10-16 1989-10-16
US50418590A 1990-04-04 1990-04-04

Publications (1)

Publication Number Publication Date
ATE147629T1 true ATE147629T1 (de) 1997-02-15

Family

ID=27025302

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90914995T ATE147629T1 (de) 1989-10-16 1990-10-09 Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch- immunologischer fehlfunktion

Country Status (14)

Country Link
US (1) US5958718A (de)
EP (1) EP0495831B1 (de)
JP (2) JP3256222B2 (de)
CN (1) CN1053360A (de)
AT (1) ATE147629T1 (de)
AU (1) AU647754B2 (de)
BR (1) BR9007757A (de)
DE (1) DE69029737T2 (de)
ES (1) ES2098273T3 (de)
HU (1) HUT65370A (de)
IE (1) IE903681A1 (de)
NZ (1) NZ235656A (de)
PT (1) PT95601B (de)
WO (1) WO1991005559A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279990B1 (de) * 1986-12-17 1995-07-12 Glaxo Group Limited Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
CA2120027A1 (en) * 1991-09-26 1993-04-01 William A. Carter Method of neutralizing il-1 using dsrnas
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DE202005004135U1 (de) * 2005-03-11 2005-05-19 Klocke Verpackungs-Service Gmbh Mehrkomponentenverpackung mit Applikator
US20220111005A1 (en) * 2019-02-01 2022-04-14 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
CN115595315B (zh) * 2021-06-28 2024-08-16 四川大学华西医院 核糖核酸酶i在抑制疼痛的药物中的新用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
US4795744A (en) * 1986-07-17 1989-01-03 Hem Research, Inc. Modulation of AIDS virus-related events by double-stranded RNAS
IE72103B1 (en) * 1987-08-12 1997-03-12 Hem Res Inc Promotion of host defense by systemic dsRNA treatment
EP0306347B1 (de) * 1987-09-04 1995-05-10 Hem Pharmaceuticals Corp. Diagnose von Mangelzuständen doppelsträngiger RNS
ES2066847T3 (es) * 1988-07-07 1995-03-16 Hem Pharma Corp Diagnostico y tratamiento del sindrome de fatiga cronica.

Also Published As

Publication number Publication date
HU9201196D0 (en) 1992-08-28
PT95601B (pt) 1997-08-29
HUT65370A (en) 1994-05-02
JP3177233B2 (ja) 2001-06-18
JPH05501199A (ja) 1993-03-11
ES2098273T3 (es) 1997-05-01
DE69029737T2 (de) 1997-06-19
CN1053360A (zh) 1991-07-31
AU647754B2 (en) 1994-03-31
JP3256222B2 (ja) 2002-02-12
EP0495831A4 (en) 1992-10-21
EP0495831B1 (de) 1997-01-15
AU6523390A (en) 1991-05-16
PT95601A (pt) 1991-09-13
WO1991005559A1 (en) 1991-05-02
NZ235656A (en) 1997-07-27
JP2000125899A (ja) 2000-05-09
US5958718A (en) 1999-09-28
IE903681A1 (en) 1991-04-24
DE69029737D1 (de) 1997-02-27
BR9007757A (pt) 1992-08-11
EP0495831A1 (de) 1992-07-29

Similar Documents

Publication Publication Date Title
Patterson et al. Vibratory angioedema: a hereditary type of physical hypersensitivity
Halberg et al. Some aspects of the cardiovascular and renal circadian systems
ATE147629T1 (de) Diagnose und behandlung von neuro-cognitiven störungen assoziiert mit systemisch- immunologischer fehlfunktion
ATE103493T1 (de) Diagnose und behandlung chronischer ermuedungserscheinungen.
Schultz Studies of ascorbic acid and rheumatic fever II. Test of prophylactic and therapeutic action of ascorbic acid
Hill et al. Normal ileostomy output: close relation to body size
PERERA Clinical and physiologic characteristics of chill
Bartfai et al. Effect of sulpiride on vigilance in healthy subjects
Anikiej et al. Cognitive functioning and autonomy of patients with Duchenne muscular dystrophy
Aviram Henoch-Schönlein syndrome associated with quinidine
Seltzer Neurological presentation of glandular fever
Dieden Break dancer's fracture of the fifth metatarsal
WOHL et al. ADIPOSIS DOLOROSA (DERCUM'S DISEASE): TREATMENT OF THE ASTHENIC PHASE WITH PROSTIGMINE AND AMINOACETIC ACID
Giner et al. Serum levels of ceruloplasmin as an index of the clinical evolution in schizophrenic patients
RU2104543C1 (ru) Способ диагностики рассеянного склероза
Bean Acquired Palmar Erythema and Cutaneous Vascular Spiders
RU96115737A (ru) Способ определения показаний к проведению гормонотерапии у больных генитальным эндометриозом
Cole Urinary fat and fat embolism
RU96111078A (ru) Способ выбора медикаментозного лечения тромбозов ретинальных вен
Wilson THE INTRAVENOUS GLUCOSE TOLERANCE CURVE AS AN INDEX OF LIVER FUNCTION AND LIVER REPLACEMENT THERAPY IN CASES OF HEPATIC INSUFFICIENCY
Meth Methods of determining blood pressure
DE3572033D1 (en) Method for diagnosis of a.i.d.s.
Abbott PERIODIC EDEMA OF HAND WITH SEVEN DAY CYCLE: TREATMENT WITH SYMPATHETIC GANGLIONECTOMY
Gregg The differentiation of psychotic from neurotic conditions
BIERMAN INTERNATIONAI, REVIEVV

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties